{
	"target_details": {
		"ensembl_id": "ENSG00000186827",
		"hgnc_id": "HGNC:11918",
		"uniprot_id": "P43489"
	},
	"about_target": {
		"introduction": {
			"Accession": "P43489",
			"Protein": "Tumor necrosis factor receptor superfamily member 4",
			"Gene": "TNFRSF4",
			"Status": "UniProtKB reviewed (Swiss-Prot)",
			"Organism": "Homo sapiens",
			"Protein Existence": "1: Evidence at protein level",
			"Annotation Score": 5
		},
		"summary_and_characteristics": {
			"Target ID": "ENSG00000186827",
			"Function Descriptions": "Receptor for TNFSF4/OX40L/GP34. Is a costimulatory molecule implicated in long-term T-cell immunity",
			"Synonyms": {
				"UniProt Synonyms": [
					"Tumor necrosis factor receptor superfamily member 4",
					"TNFRSF4",
					"TXGP1L",
					"CD134",
					"ACT35 antigen",
					"OX40L receptor",
					"TAX transcriptionally-activated glycoprotein 1 receptor"
				]
			}
		},
		"taxonomy": {
			"Taxonomic Identifier": 9606,
			"Organism": "Homo sapiens (Human)",
			"Taxonomic Lineage": [
				"Eukaryota",
				"Metazoa",
				"Chordata",
				"Craniata",
				"Vertebrata",
				"Euteleostomi",
				"Mammalia",
				"Eutheria",
				"Euarchontoglires",
				"Primates",
				"Haplorrhini",
				"Catarrhini",
				"Hominidae",
				"Homo"
			]
		}
	},
	"target_biology": {
		"ontology": [
			{
				"GO ID": "GO:0005515",
				"Name": "protein binding",
				"Aspect": "Molecular Function",
				"Evidence": "IPI",
				"Gene Product": "P43489",
				"Source": "PMID:16905106",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0005515"
			},
			{
				"GO ID": "GO:0006954",
				"Name": "inflammatory response",
				"Aspect": "Biological Process",
				"Evidence": "IBA",
				"Gene Product": "P43489",
				"Source": "GO_REF:0000033",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0006954"
			},
			{
				"GO ID": "GO:0006955",
				"Name": "immune response",
				"Aspect": "Biological Process",
				"Evidence": "TAS",
				"Gene Product": "P43489",
				"Source": "PMID:7510240",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0006955"
			},
			{
				"GO ID": "GO:0033209",
				"Name": "tumor necrosis factor-mediated signaling pathway",
				"Aspect": "Biological Process",
				"Evidence": "IEA",
				"Gene Product": "P43489",
				"Source": "GO_REF:0000108",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0033209"
			},
			{
				"GO ID": "GO:0042098",
				"Name": "T cell proliferation",
				"Aspect": "Biological Process",
				"Evidence": "ISS",
				"Gene Product": "P43489",
				"Source": "GO_REF:0000024",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0042098"
			},
			{
				"GO ID": "GO:0045892",
				"Name": "negative regulation of DNA-templated transcription",
				"Aspect": "Biological Process",
				"Evidence": "ISS",
				"Gene Product": "P43489",
				"Source": "GO_REF:0000024",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0045892"
			},
			{
				"GO ID": "GO:0001618",
				"Name": "virus receptor activity",
				"Aspect": "Molecular Function",
				"Evidence": "IEA",
				"Gene Product": "P43489",
				"Source": "GO_REF:0000043",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0001618"
			},
			{
				"GO ID": "GO:0046718",
				"Name": "symbiont entry into host cell",
				"Aspect": "Biological Process",
				"Evidence": "IEA",
				"Gene Product": "P43489",
				"Source": "GO_REF:0000108",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0046718"
			},
			{
				"GO ID": "GO:0009897",
				"Name": "external side of plasma membrane",
				"Aspect": "Cellular Component",
				"Evidence": "IBA",
				"Gene Product": "P43489",
				"Source": "GO_REF:0000033",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0009897"
			},
			{
				"GO ID": "GO:0009986",
				"Name": "cell surface",
				"Aspect": "Cellular Component",
				"Evidence": "ISS",
				"Gene Product": "P43489",
				"Source": "GO_REF:0000024",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0009986"
			},
			{
				"GO ID": "GO:0005031",
				"Name": "tumor necrosis factor receptor activity",
				"Aspect": "Molecular Function",
				"Evidence": "IBA",
				"Gene Product": "P43489",
				"Source": "GO_REF:0000033",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0005031"
			},
			{
				"GO ID": "GO:0043433",
				"Name": "negative regulation of DNA-binding transcription factor activity",
				"Aspect": "Biological Process",
				"Evidence": "ISS",
				"Gene Product": "P43489",
				"Source": "GO_REF:0000024",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0043433"
			},
			{
				"GO ID": "GO:0002639",
				"Name": "positive regulation of immunoglobulin production",
				"Aspect": "Biological Process",
				"Evidence": "ISS",
				"Gene Product": "P43489",
				"Source": "GO_REF:0000024",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0002639"
			},
			{
				"GO ID": "GO:0005886",
				"Name": "plasma membrane",
				"Aspect": "Cellular Component",
				"Evidence": "TAS",
				"Gene Product": "P43489",
				"Source": "Reactome:R-HSA-5692315",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0005886"
			},
			{
				"GO ID": "GO:0030890",
				"Name": "positive regulation of B cell proliferation",
				"Aspect": "Biological Process",
				"Evidence": "ISS",
				"Gene Product": "P43489",
				"Source": "GO_REF:0000024",
				"Link": "https://amigo.geneontology.org/amigo/term/GO:0030890"
			}
		],
		"protein_expressions": {
			"data": [
				{
					"blood": [
						{
							"Tissue": "erythroblast",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "mature neutrophil",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "mature eosinophil",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "granulocyte monocyte progenitor cell",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "inflammatory macrophage",
							"RNA Z-Score": 3,
							"Protein Level": 0
						},
						{
							"Tissue": "common myeloid progenitor",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "endothelial cell of umbilical vein (proliferating)",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "central memory CD4-positive, alpha-beta T cell",
							"RNA Z-Score": 3,
							"Protein Level": 0
						},
						{
							"Tissue": "effector memory CD4-positive, alpha-beta T cell",
							"RNA Z-Score": 3,
							"Protein Level": 0
						},
						{
							"Tissue": "hematopoietic multipotent progenitor cell",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "blood",
							"RNA Z-Score": 3,
							"Protein Level": 0
						},
						{
							"Tissue": "plasma cell",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "CD34-negative, CD41-positive, CD42-positive megakaryocyte cell",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "effector memory CD8-positive, alpha-beta T cell",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "CD4-positive, alpha-beta T cell",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "CD8-positive, alpha-beta T cell",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "CD14-positive, CD16-negative classical monocyte",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "CD38-negative naive B cell",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "megakaryocyte-erythroid progenitor cell",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "macrophage",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "hematopoietic stem cell",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "central memory CD8-positive, alpha-beta T cell",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "regulatory T cell",
							"RNA Z-Score": 3,
							"Protein Level": 0
						},
						{
							"Tissue": "alternatively activated macrophage",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "neutrophilic metamyelocyte",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "class switched memory B cell",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "endothelial cell of umbilical vein (resting)",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "common lymphoid progenitor",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "conventional dendritic cell",
							"RNA Z-Score": 3,
							"Protein Level": 0
						},
						{
							"Tissue": "cytotoxic CD56-dim natural killer cell",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "memory B cell",
							"RNA Z-Score": 0,
							"Protein Level": 0
						}
					]
				},
				{
					"immune organ": [
						{
							"Tissue": "mature neutrophil",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "mature eosinophil",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "CD8-positive, alpha-beta thymocyte",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "granulocyte monocyte progenitor cell",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "inflammatory macrophage",
							"RNA Z-Score": 3,
							"Protein Level": 0
						},
						{
							"Tissue": "spleen",
							"RNA Z-Score": 3,
							"Protein Level": 1
						},
						{
							"Tissue": "central memory CD4-positive, alpha-beta T cell",
							"RNA Z-Score": 3,
							"Protein Level": 0
						},
						{
							"Tissue": "effector memory CD4-positive, alpha-beta T cell",
							"RNA Z-Score": 3,
							"Protein Level": 0
						},
						{
							"Tissue": "leukocyte",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "plasma cell",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "CD4-positive, alpha-beta thymocyte",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "CD34-negative, CD41-positive, CD42-positive megakaryocyte cell",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "lymph node",
							"RNA Z-Score": 3,
							"Protein Level": 2
						},
						{
							"Tissue": "effector memory CD8-positive, alpha-beta T cell",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "CD4-positive, alpha-beta T cell",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "CD8-positive, alpha-beta T cell",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "CD14-positive, CD16-negative classical monocyte",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "CD38-negative naive B cell",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "macrophage",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "central memory CD8-positive, alpha-beta T cell",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "regulatory T cell",
							"RNA Z-Score": 3,
							"Protein Level": 0
						},
						{
							"Tissue": "CD3-positive, CD4-positive, CD8-positive, double positive thymocyte",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "alternatively activated macrophage",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "neutrophilic metamyelocyte",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "class switched memory B cell",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "EBV-transformed lymphocyte",
							"RNA Z-Score": 3,
							"Protein Level": 0
						},
						{
							"Tissue": "segmented neutrophil of bone marrow",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "conventional dendritic cell",
							"RNA Z-Score": 3,
							"Protein Level": 0
						},
						{
							"Tissue": "cytotoxic CD56-dim natural killer cell",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "memory B cell",
							"RNA Z-Score": 0,
							"Protein Level": 0
						}
					]
				},
				{
					"musculature": [
						{
							"Tissue": "skeletal muscle tissue",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "smooth muscle tissue",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "esophagus muscularis mucosa",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"skin of body": [
						{
							"Tissue": "lower leg skin",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "zone of skin",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "suprapubic skin",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"heart": [
						{
							"Tissue": "heart left ventricle",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "atrium auricular region",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "heart muscle",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "coronary artery",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "heart",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"endocrine gland": [
						{
							"Tissue": "CD8-positive, alpha-beta thymocyte",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "liver",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "CD4-positive, alpha-beta thymocyte",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "parathyroid gland",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "thyroid gland",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "pituitary gland",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "CD3-positive, CD4-positive, CD8-positive, double positive thymocyte",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "adrenal gland",
							"RNA Z-Score": 1,
							"Protein Level": 0
						}
					]
				},
				{
					"skeletal element": [
						{
							"Tissue": "granulocyte monocyte progenitor cell",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "bone marrow",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "CD34-negative, CD41-positive, CD42-positive megakaryocyte cell",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "segmented neutrophil of bone marrow",
							"RNA Z-Score": 0,
							"Protein Level": 0
						}
					]
				},
				{
					"pharynx": [
						{
							"Tissue": "nasopharynx",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "tonsil",
							"RNA Z-Score": 2,
							"Protein Level": 2
						}
					]
				},
				{
					"brain": [
						{
							"Tissue": "nucleus accumbens",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "cerebellar hemisphere",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "substantia nigra",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "amygdala",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "Brodmann (1909) area 24",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "putamen",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "hippocampus",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "caudate-putamen",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "hippocampus proper",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "cerebellum",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "prefrontal cortex",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "pituitary gland",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "temporal lobe",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "Brodmann (1909) area 9",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "hypothalamus",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "cerebral cortex",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "frontal lobe",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "brain",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "caudate nucleus",
							"RNA Z-Score": 1,
							"Protein Level": 0
						}
					]
				},
				{
					"spleen": [
						{
							"Tissue": "spleen",
							"RNA Z-Score": 3,
							"Protein Level": 1
						}
					]
				},
				{
					"lung": [
						{
							"Tissue": "lung",
							"RNA Z-Score": 3,
							"Protein Level": 0
						}
					]
				},
				{
					"reproductive organ": [
						{
							"Tissue": "uterus",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "ectocervix",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "seminal vesicle",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "endometrium",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "testis",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "ovary",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "vagina",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"reproductive structure": [
						{
							"Tissue": "uterus",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "epididymis",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "endocervix",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "ectocervix",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "placenta",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "seminal vesicle",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "endometrium",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "testis",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "fallopian tube",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "vagina",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "prostate gland",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"liver": [
						{
							"Tissue": "liver",
							"RNA Z-Score": 1,
							"Protein Level": 0
						}
					]
				},
				{
					"exocrine gland": [
						{
							"Tissue": "liver",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "saliva-secreting gland",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "minor salivary gland",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"connective tissue": [
						{
							"Tissue": "adipose tissue",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "subcutaneous adipose tissue",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "transformed skin fibroblast",
							"RNA Z-Score": 0,
							"Protein Level": 0
						}
					]
				},
				{
					"esophagus": [
						{
							"Tissue": "esophagus",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "esophagus mucosa",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "esophagus muscularis mucosa",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"tracheobronchial tree": [
						{
							"Tissue": "bronchus",
							"RNA Z-Score": 0,
							"Protein Level": 0
						}
					]
				},
				{
					"nerve": [
						{
							"Tissue": "tibial nerve",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"intestine": [
						{
							"Tissue": "sigmoid colon",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "small intestine",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "small intestine Peyer's patch",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "rectum",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "duodenum",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "colon",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "transverse colon",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "vermiform appendix",
							"RNA Z-Score": 3,
							"Protein Level": 0
						}
					]
				},
				{
					"colon": [
						{
							"Tissue": "sigmoid colon",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "colon",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "transverse colon",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "vermiform appendix",
							"RNA Z-Score": 3,
							"Protein Level": 0
						}
					]
				},
				{
					"spinal cord": [
						{
							"Tissue": "C1 segment of cervical spinal cord",
							"RNA Z-Score": 1,
							"Protein Level": 0
						}
					]
				},
				{
					"mucosa": [
						{
							"Tissue": "esophagus mucosa",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "small intestine Peyer's patch",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "oral mucosa",
							"RNA Z-Score": 0,
							"Protein Level": 0
						},
						{
							"Tissue": "endometrium",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "esophagus muscularis mucosa",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "minor salivary gland",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"oral gland": [
						{
							"Tissue": "saliva-secreting gland",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "minor salivary gland",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"vasculature": [
						{
							"Tissue": "aorta",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "tibial artery",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "coronary artery",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"breast": [
						{
							"Tissue": "breast",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"kidney": [
						{
							"Tissue": "kidney",
							"RNA Z-Score": 1,
							"Protein Level": 0
						},
						{
							"Tissue": "cortex of kidney",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"rectum": [
						{
							"Tissue": "rectum",
							"RNA Z-Score": 1,
							"Protein Level": 0
						}
					]
				},
				{
					"esophagogastric junction": [
						{
							"Tissue": "esophagogastric junction",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"peritoneum": [
						{
							"Tissue": "greater omentum",
							"RNA Z-Score": 3,
							"Protein Level": 0
						}
					]
				},
				{
					"bladder organ": [
						{
							"Tissue": "urinary bladder",
							"RNA Z-Score": 2,
							"Protein Level": 0
						},
						{
							"Tissue": "gall bladder",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"stomach": [
						{
							"Tissue": "stomach",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				},
				{
					"pancreas": [
						{
							"Tissue": "pancreas",
							"RNA Z-Score": 2,
							"Protein Level": 0
						}
					]
				}
			]
		},
		"subcellular": [
			{
				"Type": "Topological domain",
				"Positions": "29-214",
				"Description": "Extracellular",
				"Description Link": "https://www.ebi.ac.uk/QuickGO/term/ECO:0000255",
				"Blast Link": "https://www.uniprot.org/blast?ids=P43489[29-214]"
			},
			{
				"Type": "Transmembrane",
				"Positions": "215-235",
				"Description": "Helical",
				"Description Link": "https://www.ebi.ac.uk/QuickGO/term/ECO:0000255",
				"Blast Link": "https://www.uniprot.org/blast?ids=P43489[215-235]"
			},
			{
				"Type": "Topological domain",
				"Positions": "236-277",
				"Description": "Cytoplasmic",
				"Description Link": "https://www.ebi.ac.uk/QuickGO/term/ECO:0000255",
				"Blast Link": "https://www.uniprot.org/blast?ids=P43489[236-277]"
			}
		]
	},
	"competitive_landscape": {
		"known_drugs": [
			{
				"Drug": "ROCATINLIMAB",
				"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4594567",
				"Type": "Antibody",
				"Mechanism of Action": "Tumor necrosis factor receptor superfamily member 4 antagonist",
				"Disease": "atopic eczema",
				"Disease URL": "https://platform.opentargets.org/disease/EFO_0000274",
				"Phase": "Phase 3",
				"Status": "Completed",
				"Source URLs": [
					"https://clinicaltrials.gov/study/NCT05651711",
					"https://clinicaltrials.gov/study/NCT05899816"
				],
				"Sponsor": "Kyowa Kirin Co., Ltd.",
				"Partners": "Amgen Inc."
			},
			{
				"Drug": "TELAZORLIMAB",
				"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4594546",
				"Type": "Antibody",
				"Mechanism of Action": "Tumor necrosis factor receptor superfamily member 4 antagonist",
				"Disease": "atopic eczema",
				"Disease URL": "https://platform.opentargets.org/disease/EFO_0000274",
				"Phase": "Phase 2",
				"Status": "Completed",
				"Source URLs": [
					"https://clinicaltrials.gov/study/NCT03568162",
					"https://clinicaltrials.gov/study/NCT02683928"
				],
				"Sponsor": "Ichnos Sciences SA",
				"Partners": "Astria Therapeutics Inc"
			}
		],
		"safety": {
			"error": "No Safety events found for target"
		}
	},
	"target_prioritisation": {
		"targetability": {
			"Approved Symbol": "TNFRSF4",
			"Prioritisation": {
				"Target in clinic": 0.75,
				"Membrane protein": 0,
				"Secreted protein": 0,
				"Ligand binder": 0,
				"Small molecule binder": 0,
				"Predicted pockets": 0,
				"Mouse ortholog identity": 0,
				"Chemical probes": "no data",
				"Genetic constraint": 0.47197332777662004,
				"Mouse models": 0,
				"Gene essentiality": 0,
				"Known safety events": "no data",
				"Cancer driver gene": "no data",
				"Paralogues": 0,
				"Tissue specificity": 0.5,
				"Tissue distribution": 0
			}
		},
		"tractability": {
			"Small molecule": {
				"Items": {
					"Approved Drug": {
						"Value": false,
						"Link": ""
					},
					"Advanced Clinical": {
						"Value": false,
						"Link": ""
					},
					"Phase 1 Clinical": {
						"Value": false,
						"Link": ""
					},
					"Structure with Ligand": {
						"Value": false,
						"Link": ""
					},
					"High-Quality Ligand": {
						"Value": false,
						"Link": ""
					},
					"High-Quality Pocket": {
						"Value": false,
						"Link": ""
					},
					"Med-Quality Pocket": {
						"Value": false,
						"Link": ""
					},
					"Druggable Family": {
						"Value": false,
						"Link": ""
					}
				},
				"Links": []
			},
			"Antibody": {
				"Items": {
					"Approved Drug": {
						"Value": false,
						"Link": ""
					},
					"Advanced Clinical": {
						"Value": true,
						"Link": ""
					},
					"Phase 1 Clinical": {
						"Value": false,
						"Link": ""
					},
					"UniProt loc high conf": {
						"Value": false,
						"Link": ""
					},
					"GO CC high conf": {
						"Value": true,
						"Link": ""
					},
					"UniProt loc med conf": {
						"Value": false,
						"Link": ""
					},
					"UniProt SigP or TMHMM": {
						"Value": true,
						"Link": ""
					},
					"GO CC med conf": {
						"Value": false,
						"Link": ""
					},
					"Human Protein Atlas loc": {
						"Value": false,
						"Link": ""
					}
				},
				"Links": []
			},
			"PROTAC": {
				"Items": {
					"Approved Drug": {
						"Value": false,
						"Link": ""
					},
					"Advanced Clinical": {
						"Value": false,
						"Link": ""
					},
					"Phase 1 Clinical": {
						"Value": false,
						"Link": ""
					},
					"Literature": {
						"Value": false,
						"Link": ""
					},
					"UniProt Ubiquitination": {
						"Value": false,
						"Link": ""
					},
					"Database Ubiquitination": {
						"Value": false,
						"Link": ""
					},
					"Half-life Data": {
						"Value": false,
						"Link": ""
					},
					"Small Molecule Binder": {
						"Value": false,
						"Link": ""
					}
				},
				"Links": []
			},
			"Other modalities": {
				"Items": {
					"Approved Drug": {
						"Value": false,
						"Link": ""
					},
					"Advanced Clinical": {
						"Value": true,
						"Link": ""
					},
					"Phase 1 Clinical": {
						"Value": false,
						"Link": ""
					}
				},
				"Links": []
			}
		}
	},
	"disease_association": [],
	"mouse_phenotypes": {
		"abnormal CD4-positive, alpha-beta T cell physiology": {
			"Gene": {
				"Name": "Tnfrsf4",
				"Link": "https://www.informatics.jax.org/marker/MGI:104512"
			},
			"Phenotype": {
				"Label": "abnormal CD4-positive, alpha-beta T cell physiology",
				"Link": "https://www.ebi.ac.uk/ols4/ontologies/mp/terms?obo_id=MP:0005463"
			},
			"Categories": [
				{
					"Label": "hematopoietic system phenotype",
					"Link": "https://www.ebi.ac.uk/ols4/ontologies/mp/classes?obo_id=MP:0005397"
				},
				{
					"Label": "immune system phenotype",
					"Link": "https://www.ebi.ac.uk/ols4/ontologies/mp/classes?obo_id=MP:0005387"
				}
			],
			"Allelic Compositions": [
				{
					"Composition": "Tnfrsf4<tm1Mfb>/Tnfrsf4<tm1Mfb>",
					"Link": "https://www.informatics.jax.org/allele/genoview/MGI:3576367"
				},
				{
					"Composition": "Tnfrsf4<tm1Nik>/Tnfrsf4<tm1Nik>",
					"Link": "https://www.informatics.jax.org/allele/genoview/MGI:3034091"
				}
			]
		},
		"decreased T cell proliferation": {
			"Gene": {
				"Name": "Tnfrsf4",
				"Link": "https://www.informatics.jax.org/marker/MGI:104512"
			},
			"Phenotype": {
				"Label": "decreased T cell proliferation",
				"Link": "https://www.ebi.ac.uk/ols4/ontologies/mp/terms?obo_id=MP:0005095"
			},
			"Categories": [
				{
					"Label": "hematopoietic system phenotype",
					"Link": "https://www.ebi.ac.uk/ols4/ontologies/mp/classes?obo_id=MP:0005397"
				},
				{
					"Label": "immune system phenotype",
					"Link": "https://www.ebi.ac.uk/ols4/ontologies/mp/classes?obo_id=MP:0005387"
				},
				{
					"Label": "cellular phenotype",
					"Link": "https://www.ebi.ac.uk/ols4/ontologies/mp/classes?obo_id=MP:0005384"
				}
			],
			"Allelic Compositions": [
				{
					"Composition": "Tnfrsf4<tm1Nik>/Tnfrsf4<tm1Nik>",
					"Link": "https://www.informatics.jax.org/allele/genoview/MGI:3034091"
				}
			]
		},
		"abnormal T-helper 2 physiology": {
			"Gene": {
				"Name": "Tnfrsf4",
				"Link": "https://www.informatics.jax.org/marker/MGI:104512"
			},
			"Phenotype": {
				"Label": "abnormal T-helper 2 physiology",
				"Link": "https://www.ebi.ac.uk/ols4/ontologies/mp/terms?obo_id=MP:0005466"
			},
			"Categories": [
				{
					"Label": "hematopoietic system phenotype",
					"Link": "https://www.ebi.ac.uk/ols4/ontologies/mp/classes?obo_id=MP:0005397"
				},
				{
					"Label": "immune system phenotype",
					"Link": "https://www.ebi.ac.uk/ols4/ontologies/mp/classes?obo_id=MP:0005387"
				}
			],
			"Allelic Compositions": [
				{
					"Composition": "Tnfrsf4<tm1Nik>/Tnfrsf4<tm1Nik>",
					"Link": "https://www.informatics.jax.org/allele/genoview/MGI:3034091"
				}
			]
		},
		"decreased susceptibility to type I hypersensitivity reaction": {
			"Gene": {
				"Name": "Tnfrsf4",
				"Link": "https://www.informatics.jax.org/marker/MGI:104512"
			},
			"Phenotype": {
				"Label": "decreased susceptibility to type I hypersensitivity reaction",
				"Link": "https://www.ebi.ac.uk/ols4/ontologies/mp/terms?obo_id=MP:0005597"
			},
			"Categories": [
				{
					"Label": "immune system phenotype",
					"Link": "https://www.ebi.ac.uk/ols4/ontologies/mp/classes?obo_id=MP:0005387"
				}
			],
			"Allelic Compositions": [
				{
					"Composition": "Tnfrsf4<tm1Nik>/Tnfrsf4<tm1Nik>",
					"Link": "https://www.informatics.jax.org/allele/genoview/MGI:3034091"
				}
			]
		}
	},
	"off_target_effects": {
		"human": [
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "2.26",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987266",
				"Gene2 Symbol": "NGFR",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "NP_002498",
				"Alignment Length": "359",
				"Identity Score": "0.23",
				"Similarity Score": "0.32",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0009058(biosynthetic process);GO:0048856(anatomical structure development);GO:0006464(cellular protein modification process);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0034641(cellular nitrogen compound metabolic process);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "wgn(DIOPT=1,1);",
				"Common Protein Interactors": "2",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "7",
				"Tissue Expression Correlation": "0.08715",
				"Cell Line Expression Correlation": "0.05917"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "2.24",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987264",
				"Gene2 Symbol": "TNFRSF9",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "NP_001552",
				"Alignment Length": "272",
				"Identity Score": "0.23",
				"Similarity Score": "0.31",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "3",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "0",
				"Tissue Expression Correlation": "0.59752",
				"Cell Line Expression Correlation": "0.11615"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "2.24",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987271",
				"Gene2 Symbol": "TNFRSF6B",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "NP_003814",
				"Alignment Length": "303",
				"Identity Score": "0.25",
				"Similarity Score": "0.31",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "8",
				"Tissue Expression Correlation": "0.31386",
				"Cell Line Expression Correlation": "-0.06868"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "2.15",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987263",
				"Gene2 Symbol": "CD40",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "XP_016883624",
				"Alignment Length": "303",
				"Identity Score": "0.22",
				"Similarity Score": "0.30",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0009058(biosynthetic process);GO:0048856(anatomical structure development);GO:0006464(cellular protein modification process);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0034641(cellular nitrogen compound metabolic process);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "4",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "9",
				"Tissue Expression Correlation": "0.47723",
				"Cell Line Expression Correlation": "0.09880"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "2.09",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987261",
				"Gene2 Symbol": "CD27",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "XP_016875721",
				"Alignment Length": "318",
				"Identity Score": "0.23",
				"Similarity Score": "0.32",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "3",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "5",
				"Tissue Expression Correlation": "0.54823",
				"Cell Line Expression Correlation": "0.14906"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "2.09",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987278",
				"Gene2 Symbol": "RELT",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "XP_024304494",
				"Alignment Length": "330",
				"Identity Score": "0.26",
				"Similarity Score": "0.35",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "6",
				"Tissue Expression Correlation": "0.47792",
				"Cell Line Expression Correlation": "0.18705"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "2.02",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987272",
				"Gene2 Symbol": "TNFRSF18",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "XP_016858211",
				"Alignment Length": "279",
				"Identity Score": "0.24",
				"Similarity Score": "0.32",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "3",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "5",
				"Tissue Expression Correlation": "0.21894",
				"Cell Line Expression Correlation": "0.44558"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "1.99",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987276",
				"Gene2 Symbol": "TNFRSF10A",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "NP_003835",
				"Alignment Length": "348",
				"Identity Score": "0.22",
				"Similarity Score": "0.30",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "8",
				"Tissue Expression Correlation": "0.57689",
				"Cell Line Expression Correlation": "0.04708"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "1.98",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987262",
				"Gene2 Symbol": "TNFRSF8",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "NP_001234",
				"Alignment Length": "332",
				"Identity Score": "0.24",
				"Similarity Score": "0.33",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0009058(biosynthetic process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "4",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "3",
				"Tissue Expression Correlation": "0.28688",
				"Cell Line Expression Correlation": "0.41371"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "1.91",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987270",
				"Gene2 Symbol": "TNFRSF14",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "XP_016858207",
				"Alignment Length": "286",
				"Identity Score": "0.23",
				"Similarity Score": "0.29",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0044403(symbiosis, encompassing mutualism through parasitism);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "4",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "10",
				"Tissue Expression Correlation": "0.71722",
				"Cell Line Expression Correlation": "0.19370"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "1.86",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987275",
				"Gene2 Symbol": "TNFRSF10B",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "NP_003833",
				"Alignment Length": "294",
				"Identity Score": "0.20",
				"Similarity Score": "0.30",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "1",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "10",
				"Tissue Expression Correlation": "0.52082",
				"Cell Line Expression Correlation": "-0.01140"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "1.80",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987269",
				"Gene2 Symbol": "TNFRSF25",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "NP_683866",
				"Alignment Length": "262",
				"Identity Score": "0.23",
				"Similarity Score": "0.31",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "1",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "9",
				"Tissue Expression Correlation": "-0.01033",
				"Cell Line Expression Correlation": "0.05674"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "1.74",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987265",
				"Gene2 Symbol": "LTBR",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "NP_002333",
				"Alignment Length": "273",
				"Identity Score": "0.22",
				"Similarity Score": "0.29",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0044403(symbiosis, encompassing mutualism through parasitism);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "5",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "9",
				"Tissue Expression Correlation": "0.26438",
				"Cell Line Expression Correlation": "-0.21033"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "1.57",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987274",
				"Gene2 Symbol": "TNFRSF10D",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "NP_003831",
				"Alignment Length": "202",
				"Identity Score": "0.25",
				"Similarity Score": "0.34",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "9",
				"Tissue Expression Correlation": "0.11057",
				"Cell Line Expression Correlation": "-0.01382"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "1.48",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987277",
				"Gene2 Symbol": "TNFRSF21",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "NP_055267",
				"Alignment Length": "205",
				"Identity Score": "0.24",
				"Similarity Score": "0.32",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "8",
				"Tissue Expression Correlation": "-0.02677",
				"Cell Line Expression Correlation": "-0.17523"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "1.39",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987260",
				"Gene2 Symbol": "FAS",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "XP_011538066",
				"Alignment Length": "169",
				"Identity Score": "0.24",
				"Similarity Score": "0.30",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "10",
				"Tissue Expression Correlation": "0.36469",
				"Cell Line Expression Correlation": "0.10767"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "1.20",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987273",
				"Gene2 Symbol": "TNFRSF11A",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "XP_011524546",
				"Alignment Length": "111",
				"Identity Score": "0.32",
				"Similarity Score": "0.40",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0009058(biosynthetic process);GO:0048856(anatomical structure development);GO:0006464(cellular protein modification process);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0034641(cellular nitrogen compound metabolic process);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "4",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "1",
				"Tissue Expression Correlation": "0.12835",
				"Cell Line Expression Correlation": "0.09281"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "1.16",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987267",
				"Gene2 Symbol": "TNFRSF11B",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "NP_002537",
				"Alignment Length": "93",
				"Identity Score": "0.29",
				"Similarity Score": "0.39",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "2",
				"Tissue Expression Correlation": "-0.00371",
				"Cell Line Expression Correlation": "-0.09007"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "1.15",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987268",
				"Gene2 Symbol": "TNFRSF1A",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "NP_001056",
				"Alignment Length": "102",
				"Identity Score": "0.25",
				"Similarity Score": "0.38",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0009058(biosynthetic process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0044403(symbiosis, encompassing mutualism through parasitism);GO:0034641(cellular nitrogen compound metabolic process);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "2",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "10",
				"Tissue Expression Correlation": "0.40330",
				"Cell Line Expression Correlation": "-0.09926"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "0.00",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987279",
				"Gene2 Symbol": "LOC254896",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "",
				"Alignment Length": "0",
				"Identity Score": "0.00",
				"Similarity Score": "0.00",
				"Common GO slim": "",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "0",
				"Tissue Expression Correlation": "0.00000",
				"Cell Line Expression Correlation": "0.00000"
			},
			{
				"Species": "human",
				"Species ID": "9606",
				"Gene1 Symbol": "TNFRSF4",
				"Paralog Score": "0.00",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/2987280",
				"Gene2 Symbol": "MIR7846",
				"1-Protein Acc": "XP_011540376",
				"2-Protein Acc": "",
				"Alignment Length": "0",
				"Identity Score": "0.00",
				"Similarity Score": "0.00",
				"Common GO slim": "",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0",
				"Coexpressed Samples": "0",
				"Tissue Expression Correlation": "0.00000",
				"Cell Line Expression Correlation": "0.00000"
			}
		],
		"mouse": [
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "2.10",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436161",
				"Gene2 Symbol": "Cd27",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "XP_006505961",
				"Alignment Length": "264",
				"Identity Score": "0.27",
				"Similarity Score": "0.39",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0009058(biosynthetic process);GO:0048856(anatomical structure development);GO:0006464(cellular protein modification process);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "1",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "2.02",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436153",
				"Gene2 Symbol": "Ngfr",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_150086",
				"Alignment Length": "316",
				"Identity Score": "0.24",
				"Similarity Score": "0.36",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0009058(biosynthetic process);GO:0048856(anatomical structure development);GO:0006464(cellular protein modification process);GO:0006950(response to stress);GO:0042592(homeostatic process);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0034641(cellular nitrogen compound metabolic process);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "wgn(DIOPT=1,1);",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "2.01",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436166",
				"Gene2 Symbol": "Tnfrsf22",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_001298074",
				"Alignment Length": "191",
				"Identity Score": "0.25",
				"Similarity Score": "0.39",
				"Common GO slim": "GO:0008219(cell death);GO:0005623(cell);GO:0005886(plasma membrane);GO:0007165(signal transduction)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.97",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436152",
				"Gene2 Symbol": "Ltbr",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_034866",
				"Alignment Length": "308",
				"Identity Score": "0.26",
				"Similarity Score": "0.34",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "1",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.95",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436163",
				"Gene2 Symbol": "Tnfrsf9",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_001070977",
				"Alignment Length": "234",
				"Identity Score": "0.25",
				"Similarity Score": "0.35",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "2",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.94",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436157",
				"Gene2 Symbol": "Tnfrsf18",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "XP_017175602",
				"Alignment Length": "262",
				"Identity Score": "0.25",
				"Similarity Score": "0.34",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.94",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436167",
				"Gene2 Symbol": "Tnfrsf25",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "XP_006539381",
				"Alignment Length": "317",
				"Identity Score": "0.23",
				"Similarity Score": "0.32",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.94",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436169",
				"Gene2 Symbol": "Tnfrsf14",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "XP_006538893",
				"Alignment Length": "210",
				"Identity Score": "0.29",
				"Similarity Score": "0.39",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.92",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436151",
				"Gene2 Symbol": "Fas",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_032013",
				"Alignment Length": "257",
				"Identity Score": "0.27",
				"Similarity Score": "0.36",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0042592(homeostatic process);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.91",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436159",
				"Gene2 Symbol": "Tnfrsf1b",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_035740",
				"Alignment Length": "320",
				"Identity Score": "0.24",
				"Similarity Score": "0.34",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.91",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436170",
				"Gene2 Symbol": "Tnfrsf26",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_783580",
				"Alignment Length": "170",
				"Identity Score": "0.26",
				"Similarity Score": "0.41",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.85",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436162",
				"Gene2 Symbol": "Tnfrsf8",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_033427",
				"Alignment Length": "291",
				"Identity Score": "0.25",
				"Similarity Score": "0.33",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0009058(biosynthetic process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0034641(cellular nitrogen compound metabolic process);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.80",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436160",
				"Gene2 Symbol": "Cd40",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_035741",
				"Alignment Length": "189",
				"Identity Score": "0.28",
				"Similarity Score": "0.40",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0009058(biosynthetic process);GO:0048856(anatomical structure development);GO:0006464(cellular protein modification process);GO:0006950(response to stress);GO:0042592(homeostatic process);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0034641(cellular nitrogen compound metabolic process);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "2",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.76",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436156",
				"Gene2 Symbol": "Tnfrsf11a",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_033425",
				"Alignment Length": "302",
				"Identity Score": "0.25",
				"Similarity Score": "0.34",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0009058(biosynthetic process);GO:0048856(anatomical structure development);GO:0006464(cellular protein modification process);GO:0006950(response to stress);GO:0042592(homeostatic process);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0034641(cellular nitrogen compound metabolic process);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "2",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.76",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436165",
				"Gene2 Symbol": "Tnfrsf23",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "XP_006508723",
				"Alignment Length": "163",
				"Identity Score": "0.25",
				"Similarity Score": "0.38",
				"Common GO slim": "GO:0008219(cell death);GO:0005623(cell);GO:0005886(plasma membrane);GO:0007165(signal transduction)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.73",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436155",
				"Gene2 Symbol": "Tnfrsf10b",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_064671",
				"Alignment Length": "232",
				"Identity Score": "0.25",
				"Similarity Score": "0.37",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.72",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436158",
				"Gene2 Symbol": "Tnfrsf1a",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_035739",
				"Alignment Length": "258",
				"Identity Score": "0.24",
				"Similarity Score": "0.35",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0009058(biosynthetic process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0034641(cellular nitrogen compound metabolic process);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "2",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.53",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436168",
				"Gene2 Symbol": "Tnfrsf21",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_848704",
				"Alignment Length": "234",
				"Identity Score": "0.24",
				"Similarity Score": "0.35",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006810(transport);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.43",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436154",
				"Gene2 Symbol": "Tnfrsf11b",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_032790",
				"Alignment Length": "153",
				"Identity Score": "0.27",
				"Similarity Score": "0.39",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0042592(homeostatic process);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.22",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436171",
				"Gene2 Symbol": "Relt",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_001345843",
				"Alignment Length": "107",
				"Identity Score": "0.31",
				"Similarity Score": "0.39",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			},
			{
				"Species": "mouse",
				"Species ID": "10090",
				"Gene1 Symbol": "Tnfrsf4",
				"Paralog Score": "1.15",
				"DIOPT Score": "1",
				"Paralog Pair URL": "https://www.flyrnai.org/tools/paralogs/web/expression/3436164",
				"Gene2 Symbol": "Nradd",
				"1-Protein Acc": "XP_006538787",
				"2-Protein Acc": "NP_080288",
				"Alignment Length": "45",
				"Identity Score": "0.36",
				"Similarity Score": "0.49",
				"Common GO slim": "GO:0004871(signal transducer activity);GO:0008219(cell death);GO:0006464(cellular protein modification process);GO:0048856(anatomical structure development);GO:0006950(response to stress);GO:0005623(cell);GO:0005886(plasma membrane);GO:0008283(cell proliferation);GO:0007165(signal transduction);GO:0002376(immune system process)",
				"Common Yeast Paralogs": "",
				"Common Fly Paralogs": "",
				"Common Protein Interactors": "0",
				"Common Genetic Interactors": "0"
			}
		],
		"worm": [],
		"zebrafish": []
	},
	"publications": [
		{
			"diseasePhenotype": "Atopic dermatitis",
			"publication": "Atopic dermatitis: an expanding therapeutic pipeline for a complex disease",
			"PMID": "34417579",
			"authors": "Bieber T",
			"pmcId": "PMC8377708",
			"year": 2021,
			"pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/34417579/"
		},
		{
			"diseasePhenotype": "Atopic dermatitis",
			"publication": "OX40-OX40L Inhibition for the Treatment of Atopic DermatitisFocus on Rocatinlimab and Amlitelimab",
			"PMID": "36559247",
			"authors": "Ana Maria L and Tiago Torres",
			"pmcId": "PMC9787630",
			"year": 2022,
			"pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/36559247/"
		},
		{
			"diseasePhenotype": "Atopic dermatitis",
			"publication": "Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches",
			"PMID": "30825336",
			"authors": "Matthew Moyle, Ferda Cevikbas, Jamie L. Harden, and Emma GuttmanYassky",
			"pmcId": "PMC6850480",
			"year": 2019,
			"pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30825336/"
		},
		{
			"diseasePhenotype": "Atopic dermatitis",
			"publication": "Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives",
			"PMID": "38474389",
			"authors": "Ashutosh Pareek, Lipika Kumari, Aaushi Pareek, Simran Chaudhary, Yashumati Ratan, Pracheta Janmeda, Sanam Chuturgoon, and Anil Chuturgoon",
			"pmcId": "PMC10931328",
			"year": 2024,
			"pubmed_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10931328/"
		},
		{
			"diseasePhenotype": "Atopic dermatitis",
			"publication": "The OX40 Axis is Associated with Both Systemic and Local Involvement in Atopic Dermatitis",
			"PMID": "32176307",
			"authors": "Elsner JS, Carlsson M, Stougaard JK, Nygaard U, Buchner M, Flster-Holst R, Hvid M, Vestergaard C, Deleuran M, Deleuran B",
			"pmcId": "PMC9128899",
			"year": 2020,
			"pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/32176307/"
		},
		{
			"diseasePhenotype": "Hidradenitis suppurativa",
			"publication": "Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis",
			"PMID": "566715",
			"authors": "Gudjonsson JE, Tsoi LC, Ma F, Billi AC, van Straalen KR, Vossen ARJV, van der Zee HH, Harms PW, Wasikowski R, Yee CM, Rizvi SM, Xing X, Xing E, Plazyo O, Zeng C, Patrick MT, Lowe MM, Burney RE, Kozlow JH, Cherry-Bukowiec JR, Jiang Y, Kirma J, Weidinger S, Cushing KC, Rosenblum MD, Berthier C, MacLeod AS, Voorhees JJ, Wen F, Kahlenberg JM, Maverakis E, Modlin RL, Prens EP.",
			"pmcId": "PMC7566715",
			"year": 2020,
			"pubmed_url": "https://ncbi.nlm.nih.gov/pmc/articles/PMC7566715/"
		},
		{
			"diseasePhenotype": "Hidradenitis suppurativa",
			"publication": "Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug RepurposingA Molecular Meta-Analysis",
			"PMID": "35056940",
			"authors": "Viktor A. Zouboulis, Konstantin C. Zouboulis and Christos C. Zouboulis",
			"pmcId": "PMC8779519",
			"year": 2022,
			"pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/35056940/"
		},
		{
			"diseasePhenotype": "Systemic sclerosis",
			"publication": "Targeting Costimulatory Pathways in Systemic Sclerosis",
			"PMID": "30619351",
			"authors": "Gonalo Boleto, Yannick Allanore and Jrme Avouac",
			"pmcId": "PMC6305435",
			"year": 2018,
			"pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30619351/"
		},
		{
			"diseasePhenotype": "Systemic sclerosis",
			"publication": "TNF superfamily control of tissue remodeling and fibrosis",
			"PMID": "37465675",
			"authors": "Hope Steele, Jason Cheng, Ashley Willicut, Garrison Dell, Joey Breckenridge, Erica Culberson, Andrew Ghastine, Virginie Tardif and Rana Herro",
			"pmcId": "PMC10351606",
			"year": 2023,
			"pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/37465675/"
		},
		{
			"diseasePhenotype": "Systemic sclerosis",
			"publication": "Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis",
			"PMID": "19778912",
			"authors": "Gourh, Pravitt et al.",
			"pmcId": "PMC2927683",
			"year": 2010,
			"pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/19778912/"
		}
	],
	"indication_pipeline": [
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "CRISABOROLE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL484785",
			"Type": "Small molecule",
			"Mechanism of Action": "Phosphodiesterase 4 inhibitor",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "PDE4A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000065989",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03868098"],
			"Sponsor": "Innovaderm Research Inc."
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "CRISABOROLE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL484785",
			"Type": "Small molecule",
			"Mechanism of Action": "Phosphodiesterase 4 inhibitor",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "PDE4C",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105650",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03868098"],
			"Sponsor": "Innovaderm Research Inc."
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "PIMECROLIMUS",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1200686",
			"Type": "Small molecule",
			"Mechanism of Action": "FK506-binding protein 1A inhibitor",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "FKBP1A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000088832",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT00666302",
				"https://clinicaltrials.gov/study/NCT00121381",
				"https://clinicaltrials.gov/study/NCT00667160",
				"https://clinicaltrials.gov/study/NCT00666159"
			],
			"Sponsor": "Astellas Pharma Inc"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "BETAMETHASONE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL632",
			"Type": "Small molecule",
			"Mechanism of Action": "Glucocorticoid receptor agonist",
			"Phase": "Phase 4",
			"Status": "Terminated",
			"Target": "NR3C1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113580",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00671528"],
			"Sponsor": "Organon and Co"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "CRISABOROLE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL484785",
			"Type": "Small molecule",
			"Mechanism of Action": "Phosphodiesterase 4 inhibitor",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "PDE4D",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113448",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03868098"],
			"Sponsor": "Innovaderm Research Inc."
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "MONTELUKAST",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL787",
			"Type": "Small molecule",
			"Mechanism of Action": "Cysteinyl leukotriene receptor 1 antagonist",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "CYSLTR1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000173198",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02534467"],
			"Sponsor": "Murdoch Childrens Research Institute"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "BETAMETHASONE DIPROPIONATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1200384",
			"Type": "Small molecule",
			"Mechanism of Action": "Glucocorticoid receptor agonist",
			"Phase": "Phase 4",
			"Status": "Terminated",
			"Target": "NR3C1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113580",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00671528"],
			"Sponsor": "Organon and Co"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "DUPILUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2108675",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-4 receptor subunit alpha antagonist",
			"Phase": "Phase 4",
			"Status": "Recruiting",
			"Target": "IL4R",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000077238",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05642208"],
			"Sponsor": "Regeneron Pharmaceuticals"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "FLUTICASONE PROPIONATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1473",
			"Type": "Small molecule",
			"Mechanism of Action": "Glucocorticoid receptor agonist",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "NR3C1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113580",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT00690105",
				"https://clinicaltrials.gov/study/NCT00689832"
			],
			"Sponsor": "Astellas Pharma Inc"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "TACROLIMUS ANHYDROUS",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL269732",
			"Type": "Small molecule",
			"Mechanism of Action": "FK506-binding protein 1A inhibitor",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "FKBP1A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000088832",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT00689832",
				"https://clinicaltrials.gov/study/NCT00667160",
				"https://clinicaltrials.gov/study/NCT00666159",
				"https://clinicaltrials.gov/study/NCT00690105",
				"https://clinicaltrials.gov/study/NCT00106496",
				"https://clinicaltrials.gov/study/NCT01782729",
				"https://clinicaltrials.gov/study/NCT00666302",
				"https://clinicaltrials.gov/study/NCT01828879"
			],
			"Sponsor": "Astellas Pharma Inc"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "CRISABOROLE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL484785",
			"Type": "Small molecule",
			"Mechanism of Action": "Phosphodiesterase 4 inhibitor",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "PDE4B",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000184588",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03868098"],
			"Sponsor": "Innovaderm Research Inc."
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "TRIAMCINOLONE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1451",
			"Type": "Small molecule",
			"Mechanism of Action": "Glucocorticoid receptor agonist",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "NR3C1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113580",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02680301"],
			"Sponsor": "Seton Healthcare Family"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "ABROCITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL3655081",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase JAK1 inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "JAK1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000162434",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03349060",
				"https://clinicaltrials.gov/study/NCT03575871"
			],
			"Sponsor": "Pfizer"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "CETIRIZINE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1000",
			"Type": "Small molecule",
			"Mechanism of Action": "Histamine H1 receptor antagonist",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "HRH1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196639",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00257569"],
			"Sponsor": "GlaxoSmithKline"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "LEVOCETIRIZINE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201191",
			"Type": "Small molecule",
			"Mechanism of Action": "Histamine H1 receptor antagonist",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "HRH1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196639",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00152464"],
			"Sponsor": "UCB Pharma"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "KETOTIFEN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL534",
			"Type": "Small molecule",
			"Mechanism of Action": "Histamine H1 receptor antagonist",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "HRH1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196639",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02182557"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "DESLORATADINE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1172",
			"Type": "Small molecule",
			"Mechanism of Action": "Histamine H1 receptor antagonist",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "HRH1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196639",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00817076"],
			"Sponsor": "Organon and Co"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "KETOTIFEN FUMARATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1633",
			"Type": "Small molecule",
			"Mechanism of Action": "Histamine H1 receptor antagonist",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "HRH1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196639",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02182557"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "SECUKINUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1743068",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin 17A inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL17A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000112115",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03568136"],
			"Sponsor": "GWT-TUD GmbH"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "SPESOLIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297911",
			"Type": "Antibody",
			"Mechanism of Action": "IL36 receptor antagonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL1RL2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000115598",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03822832"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "SPESOLIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297911",
			"Type": "Antibody",
			"Mechanism of Action": "IL36 receptor antagonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL1RAP",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196083",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03822832"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "DOXYCYCLINE ANHYDROUS",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1433",
			"Type": "Small molecule",
			"Mechanism of Action": "Matrix metalloproteinase-1 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "MMP1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196611",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02910011"],
			"Sponsor": "University of Florida"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "ROVAZOLAC",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297218",
			"Type": "Small molecule",
			"Mechanism of Action": "Liver X receptor agonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "NR1H2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000131408",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03175354"],
			"Sponsor": "Ralexar Therapeutics, Inc."
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "DOXYCYCLINE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1200699",
			"Type": "Small molecule",
			"Mechanism of Action": "Matrix metalloproteinase 13 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "MMP13",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000137745",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02910011"],
			"Sponsor": "University of Florida"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "DOXYCYCLINE ANHYDROUS",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1433",
			"Type": "Small molecule",
			"Mechanism of Action": "Matrix metalloproteinase 13 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "MMP13",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000137745",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02910011"],
			"Sponsor": "University of Florida"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "BERMEKIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2109653",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-1 alpha inhibitor",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "IL1A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000115008",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT04990440",
				"https://clinicaltrials.gov/study/NCT04791319"
			],
			"Sponsor": "Janssen Research &amp; Development, LLC"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "TOFACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL221959",
			"Type": "Small molecule",
			"Mechanism of Action": "Janus Kinase (JAK) inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "JAK3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105639",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02001181"],
			"Sponsor": "Pfizer"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "DOXYCYCLINE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1200699",
			"Type": "Small molecule",
			"Mechanism of Action": "Matrix metalloproteinase-1 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "MMP1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196611",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02910011"],
			"Sponsor": "University of Florida"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "DOXYCYCLINE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1200699",
			"Type": "Small molecule",
			"Mechanism of Action": "Matrix metalloproteinase 8 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "MMP8",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000118113",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02910011"],
			"Sponsor": "University of Florida"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "DOXYCYCLINE ANHYDROUS",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1433",
			"Type": "Small molecule",
			"Mechanism of Action": "Matrix metalloproteinase 8 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "MMP8",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000118113",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02910011"],
			"Sponsor": "University of Florida"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "NEMOLIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297794",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-31 receptor subunit alpha inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL31RA",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000164509",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04365387"],
			"Sponsor": "Galderma R&amp;D"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "GSK-1070806",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2109606",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-18 inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "IL18",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000150782",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT04975438",
				"https://clinicaltrials.gov/study/NCT05590338"
			],
			"Sponsor": "GlaxoSmithKline"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "USTEKINUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201835",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-23 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL12B",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113302",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01945086"],
			"Sponsor": "Janssen Pharmaceutical K.K."
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "DOXYCYCLINE ANHYDROUS",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1433",
			"Type": "Small molecule",
			"Mechanism of Action": "Matrix metalloproteinase 7 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "MMP7",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000137673",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02910011"],
			"Sponsor": "University of Florida"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "DOXYCYCLINE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1200699",
			"Type": "Small molecule",
			"Mechanism of Action": "Matrix metalloproteinase 7 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "MMP7",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000137673",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02910011"],
			"Sponsor": "University of Florida"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "BRANEBRUTINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297674",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase BTK inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "BTK",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000010671",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05014438"],
			"Sponsor": "Bristol-Myers Squibb"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "AMLITELIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4594569",
			"Type": "Antibody",
			"Mechanism of Action": "Tumor necrosis factor ligand superfamily member 4 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TNFSF4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000117586",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03754309"],
			"Sponsor": "Kymab Limited"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "TOFACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL221959",
			"Type": "Small molecule",
			"Mechanism of Action": "Janus Kinase (JAK) inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "JAK1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000162434",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02001181"],
			"Sponsor": "Pfizer"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "TAPINAROF",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL259571",
			"Type": "Small molecule",
			"Mechanism of Action": "Aryl hydrocarbon receptor agonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "AHR",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000106546",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01098734"],
			"Sponsor": "Welichem Biotech Inc."
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "EFALIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201575",
			"Type": "Antibody",
			"Mechanism of Action": "Integrin alpha-L/beta-2 (LFA-1) inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "ITGAL",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000005844",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00146003"],
			"Sponsor": "Rutgers, The State University of New Jersey"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "ROVAZOLAC",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297218",
			"Type": "Small molecule",
			"Mechanism of Action": "Liver X receptor agonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "NR1H3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000025434",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03175354"],
			"Sponsor": "Ralexar Therapeutics, Inc."
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "MEPOLIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2108429",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-5 inhibitor",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "IL5",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113525",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03055195"],
			"Sponsor": "GlaxoSmithKline"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "TOFACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL221959",
			"Type": "Small molecule",
			"Mechanism of Action": "Janus Kinase (JAK) inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TYK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105397",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02001181"],
			"Sponsor": "Pfizer"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "TOFACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL221959",
			"Type": "Small molecule",
			"Mechanism of Action": "Janus Kinase (JAK) inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "JAK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000096968",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02001181"],
			"Sponsor": "Pfizer"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "GUSACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4594275",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase SYK inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "SYK",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000165025",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03139981"],
			"Sponsor": "Asana BioSciences"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "GUSACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4594275",
			"Type": "Small molecule",
			"Mechanism of Action": "Janus Kinase (JAK) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "JAK3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105639",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03139981"],
			"Sponsor": "Asana BioSciences"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "CLOBETASOL PROPIONATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1159650",
			"Type": "Small molecule",
			"Mechanism of Action": "Glucocorticoid receptor agonist",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "NR3C1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113580",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01381445"],
			"Sponsor": "GlaxoSmithKline"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "GUSACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4594275",
			"Type": "Small molecule",
			"Mechanism of Action": "Janus Kinase (JAK) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "JAK1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000162434",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03139981"],
			"Sponsor": "Asana BioSciences"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "GUSACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4594275",
			"Type": "Small molecule",
			"Mechanism of Action": "Janus Kinase (JAK) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "TYK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105397",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03139981"],
			"Sponsor": "Asana BioSciences"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "SB-705498",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL207433",
			"Type": "Small molecule",
			"Mechanism of Action": "Vanilloid receptor antagonist",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "TRPV1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196689",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01673529"],
			"Sponsor": "GlaxoSmithKline"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "GUSACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4594275",
			"Type": "Small molecule",
			"Mechanism of Action": "Janus Kinase (JAK) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "JAK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000096968",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03139981"],
			"Sponsor": "Asana BioSciences"
		},
		{
			"Disease": "dermatitis, atopic",
			"Disease URL": "https://platform.opentargets.org/disease/MONDO_0011292",
			"Drug": "ROCATINLIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4594567",
			"Type": "Antibody",
			"Mechanism of Action": "Tumor necrosis factor receptor superfamily member 4 antagonist",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "TNFRSF4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000186827",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03096223"],
			"Sponsor": "Kyowa Kirin Co., Ltd."
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "ASPIRIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL25",
			"Type": "Small molecule",
			"Mechanism of Action": "Cyclooxygenase inhibitor",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "PTGS2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000073756",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03558854"],
			"Sponsor": "Federal University of So Paulo"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "ASPIRIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL25",
			"Type": "Small molecule",
			"Mechanism of Action": "Cyclooxygenase inhibitor",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "PTGS1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000095303",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03558854"],
			"Sponsor": "Federal University of So Paulo"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "BARICITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2105759",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase JAK2 inhibitor",
			"Phase": "Phase 4",
			"Status": "Recruiting",
			"Target": "JAK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000096968",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05300932"],
			"Sponsor": "Tongji Hospital"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "BOSENTAN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL957",
			"Type": "Small molecule",
			"Mechanism of Action": "Endothelin receptor, ET-A/ET-B antagonist",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "EDNRB",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000136160",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT02480335",
				"https://clinicaltrials.gov/study/NCT01395732"
			],
			"Sponsor": "University Medical Center Groningen"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "BOSENTAN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL957",
			"Type": "Small molecule",
			"Mechanism of Action": "Endothelin receptor, ET-A/ET-B antagonist",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "EDNRA",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000151617",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT02480335",
				"https://clinicaltrials.gov/study/NCT01395732"
			],
			"Sponsor": "University Medical Center Groningen"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "BARICITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2105759",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase JAK1 inhibitor",
			"Phase": "Phase 4",
			"Status": "Recruiting",
			"Target": "JAK1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000162434",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05300932"],
			"Sponsor": "Tongji Hospital"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "ROSUVASTATIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1496",
			"Type": "Small molecule",
			"Mechanism of Action": "HMG-CoA reductase inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "HMGCR",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113161",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00984932"],
			"Sponsor": "University of Alexandria"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NINTEDANIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL502835",
			"Type": "Small molecule",
			"Mechanism of Action": "Fibroblast growth factor receptor inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "FGFR3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000068078",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02597933"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "SILDENAFIL",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL192",
			"Type": "Small molecule",
			"Mechanism of Action": "Phosphodiesterase 5A inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "PDE5A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000138735",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01295736"],
			"Sponsor": "University Hospital, Lille"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NINTEDANIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL502835",
			"Type": "Small molecule",
			"Mechanism of Action": "Platelet-derived growth factor receptor inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "PDGFRA",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000134853",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02597933"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NINTEDANIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL502835",
			"Type": "Small molecule",
			"Mechanism of Action": "Fibroblast growth factor receptor inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "FGFR4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000160867",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02597933"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "METHYLPREDNISOLONE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL650",
			"Type": "Small molecule",
			"Mechanism of Action": "Glucocorticoid receptor agonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "NR3C1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113580",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00379431"],
			"Sponsor": "University Hospital, Ghent"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "MACITENTAN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2103873",
			"Type": "Small molecule",
			"Mechanism of Action": "Endothelin receptor, ET-A/ET-B antagonist",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "EDNRB",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000136160",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01474109"],
			"Sponsor": "Actelion"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "CLOPIDOGREL",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1771",
			"Type": "Small molecule",
			"Mechanism of Action": "Purinergic receptor P2Y12 antagonist",
			"Phase": "Phase 3",
			"Status": "Recruiting",
			"Target": "P2RY12",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000169313",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05098704"],
			"Sponsor": "University Hospital, Bordeaux"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FLUDARABINE PHOSPHATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1096882",
			"Type": "Small molecule",
			"Mechanism of Action": "DNA polymerase (alpha/delta/epsilon) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "POLD1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000062822",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FLUDARABINE PHOSPHATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1096882",
			"Type": "Small molecule",
			"Mechanism of Action": "DNA polymerase (alpha/delta/epsilon) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "PRIM1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000198056",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NINTEDANIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL502835",
			"Type": "Small molecule",
			"Mechanism of Action": "Platelet-derived growth factor receptor inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "PDGFRB",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113721",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02597933"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FLUDARABINE PHOSPHATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1096882",
			"Type": "Small molecule",
			"Mechanism of Action": "DNA polymerase (alpha/delta/epsilon) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "POLD4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000175482",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NINTEDANIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL502835",
			"Type": "Small molecule",
			"Mechanism of Action": "Fibroblast growth factor receptor inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "FGFR1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000077782",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02597933"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NINTEDANIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL502835",
			"Type": "Small molecule",
			"Mechanism of Action": "Fibroblast growth factor receptor inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "FGFR2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000066468",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02597933"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NINTEDANIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL502835",
			"Type": "Small molecule",
			"Mechanism of Action": "Vascular endothelial growth factor receptor inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "FLT1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000102755",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02597933"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NINTEDANIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL502835",
			"Type": "Small molecule",
			"Mechanism of Action": "Vascular endothelial growth factor receptor inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "FLT4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000037280",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02597933"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "INEBILIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2109334",
			"Type": "Antibody",
			"Mechanism of Action": "B-lymphocyte antigen CD19 binding agent",
			"Phase": "Phase 3",
			"Status": "Recruiting",
			"Target": "CD19",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000177455",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05198557"],
			"Sponsor": "Mitsubishi Tanabe Pharma Corporation"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "ANIFROLUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2364653",
			"Type": "Antibody",
			"Mechanism of Action": "Interferon-alpha/beta receptor alpha chain antagonist",
			"Phase": "Phase 3",
			"Status": "Recruiting",
			"Target": "IFNAR1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000142166",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05925803"],
			"Sponsor": "AstraZeneca"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FLUDARABINE PHOSPHATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1096882",
			"Type": "Small molecule",
			"Mechanism of Action": "DNA polymerase (alpha/delta/epsilon) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "PRIM2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000146143",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "SILDENAFIL CITRATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1737",
			"Type": "Small molecule",
			"Mechanism of Action": "Phosphodiesterase 5A inhibitor",
			"Phase": "Phase 3",
			"Status": "Recruiting",
			"Target": "PDE5A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000138735",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01347008"],
			"Sponsor": "Federal University of So Paulo"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FLUDARABINE PHOSPHATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1096882",
			"Type": "Small molecule",
			"Mechanism of Action": "Ribonucleoside-diphosphate reductase RR1 inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "RRM1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000167325",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NINTEDANIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL502835",
			"Type": "Small molecule",
			"Mechanism of Action": "Vascular endothelial growth factor receptor inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "KDR",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000128052",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02597933"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "TOCILIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1237022",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-6 receptor alpha subunit inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "IL6R",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000160712",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT02453256",
				"https://clinicaltrials.gov/study/NCT01532869"
			],
			"Sponsor": "Hoffmann-La Roche"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FLUDARABINE PHOSPHATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1096882",
			"Type": "Small molecule",
			"Mechanism of Action": "DNA polymerase (alpha/delta/epsilon) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "POLE3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000148229",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FLUDARABINE PHOSPHATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1096882",
			"Type": "Small molecule",
			"Mechanism of Action": "DNA polymerase (alpha/delta/epsilon) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "POLE",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000177084",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FLUDARABINE PHOSPHATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1096882",
			"Type": "Small molecule",
			"Mechanism of Action": "DNA polymerase (alpha/delta/epsilon) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "POLD3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000077514",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FLUDARABINE PHOSPHATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1096882",
			"Type": "Small molecule",
			"Mechanism of Action": "DNA polymerase (alpha/delta/epsilon) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "POLA2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000014138",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FLUDARABINE PHOSPHATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1096882",
			"Type": "Small molecule",
			"Mechanism of Action": "DNA polymerase (alpha/delta/epsilon) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "POLA1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000101868",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FILGRASTIM",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201567",
			"Type": "Protein",
			"Mechanism of Action": "Granulocyte colony stimulating factor receptor agonist",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "CSF3R",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000119535",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00058578"],
			"Sponsor": "Baylor College of Medicine"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FLUDARABINE PHOSPHATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1096882",
			"Type": "Small molecule",
			"Mechanism of Action": "DNA polymerase (alpha/delta/epsilon) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "POLD2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000106628",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "FLUDARABINE PHOSPHATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1096882",
			"Type": "Small molecule",
			"Mechanism of Action": "DNA polymerase (alpha/delta/epsilon) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "POLE2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000100479",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "MACITENTAN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2103873",
			"Type": "Small molecule",
			"Mechanism of Action": "Endothelin receptor, ET-A/ET-B antagonist",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "EDNRA",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000151617",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01474109"],
			"Sponsor": "Actelion"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "ROMILKIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4298097",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-13 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL13",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000169194",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02921971"],
			"Sponsor": "Sanofi"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "TREPROSTINIL",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1237119",
			"Type": "Small molecule",
			"Mechanism of Action": "Prostanoid IP receptor agonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "PTGIR",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000160013",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00775463"],
			"Sponsor": "United Therapeutics"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "MYCOPHENOLATE MOFETIL",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1456",
			"Type": "Small molecule",
			"Mechanism of Action": "Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IMPDH1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000106348",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01670565"],
			"Sponsor": "Hospital for Special Surgery, New York"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "RITUXIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201576",
			"Type": "Antibody",
			"Mechanism of Action": "B-lymphocyte antigen CD20 binding agent",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "MS4A1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000156738",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT01748084",
				"https://clinicaltrials.gov/study/NCT00379431"
			],
			"Sponsor": "Assistance Publique - Hpitaux de Paris"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "MYCOPHENOLATE MOFETIL",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1456",
			"Type": "Small molecule",
			"Mechanism of Action": "Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IMPDH2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000178035",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01670565"],
			"Sponsor": "Hospital for Special Surgery, New York"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NILOTINIB HYDROCHLORIDE MONOHYDRATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201740",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase ABL inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "ABL1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000097007",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01166139"],
			"Sponsor": "Hospital for Special Surgery, New York"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "BRENTUXIMAB VEDOTIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1742994",
			"Type": "Antibody drug conjugate",
			"Mechanism of Action": "Tubulin inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TUBB3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000258947",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03198689",
				"https://clinicaltrials.gov/study/NCT03222492"
			],
			"Sponsor": "Lawson Health Research Institute"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "TREPROSTINIL DIOLAMINE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2107815",
			"Type": "Small molecule",
			"Mechanism of Action": "Prostanoid IP receptor agonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "PTGIR",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000160013",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00775463"],
			"Sponsor": "United Therapeutics"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "BRENTUXIMAB VEDOTIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1742994",
			"Type": "Antibody drug conjugate",
			"Mechanism of Action": "Tubulin inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TUBB2A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000137267",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03198689",
				"https://clinicaltrials.gov/study/NCT03222492"
			],
			"Sponsor": "Lawson Health Research Institute"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NILOTINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL255863",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase ABL inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "ABL1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000097007",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01166139"],
			"Sponsor": "Hospital for Special Surgery, New York"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "BELIMUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1789843",
			"Type": "Antibody",
			"Mechanism of Action": "Tumor necrosis factor ligand superfamily member 13B inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TNFSF13B",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000102524",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01670565"],
			"Sponsor": "Hospital for Special Surgery, New York"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "BELUMOSUDIL",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2005186",
			"Type": "Small molecule",
			"Mechanism of Action": "Rho-associated protein kinase inhibitor",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "ROCK1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000067900",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03919799",
				"https://clinicaltrials.gov/study/NCT04680975"
			],
			"Sponsor": "Sanofi"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "BRENTUXIMAB VEDOTIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1742994",
			"Type": "Antibody drug conjugate",
			"Mechanism of Action": "Tubulin inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TUBB8",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000261456",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03198689",
				"https://clinicaltrials.gov/study/NCT03222492"
			],
			"Sponsor": "Lawson Health Research Institute"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "BRENTUXIMAB VEDOTIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1742994",
			"Type": "Antibody drug conjugate",
			"Mechanism of Action": "Tubulin inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TUBB6",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000176014",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03222492",
				"https://clinicaltrials.gov/study/NCT03198689"
			],
			"Sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "RIOCIGUAT",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2107834",
			"Type": "Small molecule",
			"Mechanism of Action": "Soluble guanylate cyclase positive allosteric modulator",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "GUCY1A1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000164116",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02283762"],
			"Sponsor": "Bayer"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NILOTINIB HYDROCHLORIDE MONOHYDRATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201740",
			"Type": "Small molecule",
			"Mechanism of Action": "Bcr/Abl fusion protein",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "BCR",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000186716",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01166139"],
			"Sponsor": "Hospital for Special Surgery, New York"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "BRENTUXIMAB VEDOTIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1742994",
			"Type": "Antibody drug conjugate",
			"Mechanism of Action": "Tubulin inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TUBB",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196230",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03222492",
				"https://clinicaltrials.gov/study/NCT03198689"
			],
			"Sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "IMATINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL941",
			"Type": "Small molecule",
			"Mechanism of Action": "Bcr/Abl fusion protein",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "BCR",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000186716",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT00613171",
				"https://clinicaltrials.gov/study/NCT00479934",
				"https://clinicaltrials.gov/study/NCT00555581"
			],
			"Sponsor": "Novartis"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "PEMBROLIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL3137343",
			"Type": "Antibody",
			"Mechanism of Action": "Programmed cell death protein 1 inhibitor",
			"Phase": "Phase 2",
			"Status": "Active, not recruiting",
			"Target": "PDCD1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000188389",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04812535"],
			"Sponsor": "InflaRx GmbH"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "ROMILKIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4298097",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-4 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113520",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02921971"],
			"Sponsor": "Sanofi"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "POMALIDOMIDE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL43452",
			"Type": "Small molecule",
			"Mechanism of Action": "CRL4(CRBN) E3 ubiquitin ligase inhibitor",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "CUL4A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000139842",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01559129"],
			"Sponsor": "Celgene"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "ILOPROST",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL494",
			"Type": "Small molecule",
			"Mechanism of Action": "Prostanoid IP receptor agonist",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "PTGIR",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000160013",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622687"],
			"Sponsor": "Charite University, Berlin, Germany"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "BELUMOSUDIL",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2005186",
			"Type": "Small molecule",
			"Mechanism of Action": "Rho-associated protein kinase 2 inhibitor",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "ROCK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000134318",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03919799",
				"https://clinicaltrials.gov/study/NCT04680975"
			],
			"Sponsor": "Sanofi"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "ABITUZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2109621",
			"Type": "Antibody",
			"Mechanism of Action": "Integrin alpha-V/beta-8 inhibitor",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "ITGAV",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000138448",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02745145"],
			"Sponsor": "EMD Serono"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "IMATINIB MESYLATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1642",
			"Type": "Small molecule",
			"Mechanism of Action": "Bcr/Abl fusion protein",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "BCR",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000186716",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT00555581",
				"https://clinicaltrials.gov/study/NCT00613171",
				"https://clinicaltrials.gov/study/NCT00479934"
			],
			"Sponsor": "Hospital for Special Surgery, New York"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "BRENTUXIMAB VEDOTIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1742994",
			"Type": "Antibody drug conjugate",
			"Mechanism of Action": "Tubulin inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TUBB4B",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000188229",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03198689",
				"https://clinicaltrials.gov/study/NCT03222492"
			],
			"Sponsor": "Lawson Health Research Institute"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "IMATINIB MESYLATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1642",
			"Type": "Small molecule",
			"Mechanism of Action": "Platelet-derived growth factor receptor beta inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "PDGFRB",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113721",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT00479934",
				"https://clinicaltrials.gov/study/NCT00555581",
				"https://clinicaltrials.gov/study/NCT00613171"
			],
			"Sponsor": "University Hospital, Bordeaux"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "ZIRITAXESTAT",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL3828074",
			"Type": "Small molecule",
			"Mechanism of Action": "Autotaxin inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "ENPP2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000136960",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03798366"],
			"Sponsor": "Galapagos NV"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "PLERIXAFOR",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL18442",
			"Type": "Small molecule",
			"Mechanism of Action": "C-X-C chemokine receptor type 4 partial agonist",
			"Phase": "Phase 2",
			"Status": "Active, not recruiting",
			"Target": "CXCR4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000121966",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01413100"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "IMATINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL941",
			"Type": "Small molecule",
			"Mechanism of Action": "Platelet-derived growth factor receptor beta inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "PDGFRB",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113721",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT00479934",
				"https://clinicaltrials.gov/study/NCT00613171",
				"https://clinicaltrials.gov/study/NCT00555581"
			],
			"Sponsor": "University Hospital, Bordeaux"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "POMALIDOMIDE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL43452",
			"Type": "Small molecule",
			"Mechanism of Action": "CRL4(CRBN) E3 ubiquitin ligase inhibitor",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "CRBN",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113851",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01559129"],
			"Sponsor": "Celgene"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "SIROLIMUS",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL413",
			"Type": "Small molecule",
			"Mechanism of Action": "FK506-binding protein 1A inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "FKBP1A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000088832",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00241189"],
			"Sponsor": "University of California, Los Angeles"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "TADALAFIL",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL779",
			"Type": "Small molecule",
			"Mechanism of Action": "Phosphodiesterase 5A inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "PDE5A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000138735",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00707187"],
			"Sponsor": "Rutgers, The State University of New Jersey"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "IMATINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL941",
			"Type": "Small molecule",
			"Mechanism of Action": "Stem cell growth factor receptor inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "KIT",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000157404",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT00479934",
				"https://clinicaltrials.gov/study/NCT00613171",
				"https://clinicaltrials.gov/study/NCT00555581"
			],
			"Sponsor": "University Hospital, Bordeaux"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "RIOCIGUAT",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2107834",
			"Type": "Small molecule",
			"Mechanism of Action": "Soluble guanylate cyclase positive allosteric modulator",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "GUCY1A2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000152402",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02283762"],
			"Sponsor": "Bayer"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "IMATINIB MESYLATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1642",
			"Type": "Small molecule",
			"Mechanism of Action": "Stem cell growth factor receptor inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "KIT",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000157404",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT00555581",
				"https://clinicaltrials.gov/study/NCT00613171",
				"https://clinicaltrials.gov/study/NCT00479934"
			],
			"Sponsor": "Hospital for Special Surgery, New York"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "TOFACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL221959",
			"Type": "Small molecule",
			"Mechanism of Action": "Janus Kinase (JAK) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "JAK1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000162434",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03274076"],
			"Sponsor": "University of Michigan"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "POMALIDOMIDE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL43452",
			"Type": "Small molecule",
			"Mechanism of Action": "CRL4(CRBN) E3 ubiquitin ligase inhibitor",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "DDB1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000167986",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01559129"],
			"Sponsor": "Celgene"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "TOFACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL221959",
			"Type": "Small molecule",
			"Mechanism of Action": "Janus Kinase (JAK) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "JAK3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105639",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03274076"],
			"Sponsor": "University of Michigan"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "IMATINIB MESYLATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1642",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase ABL inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "ABL1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000097007",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT00613171",
				"https://clinicaltrials.gov/study/NCT00479934",
				"https://clinicaltrials.gov/study/NCT00555581"
			],
			"Sponsor": "Novartis"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "BRENTUXIMAB VEDOTIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1742994",
			"Type": "Antibody drug conjugate",
			"Mechanism of Action": "Tubulin inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TUBB4A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000104833",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03222492",
				"https://clinicaltrials.gov/study/NCT03198689"
			],
			"Sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "IMATINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL941",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase ABL inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "ABL1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000097007",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT00613171",
				"https://clinicaltrials.gov/study/NCT00555581",
				"https://clinicaltrials.gov/study/NCT00479934"
			],
			"Sponsor": "Novartis"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "RIOCIGUAT",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2107834",
			"Type": "Small molecule",
			"Mechanism of Action": "Soluble guanylate cyclase positive allosteric modulator",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "GUCY1B2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000123201",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02283762"],
			"Sponsor": "Bayer"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NEMOLIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297794",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-31 receptor subunit alpha inhibitor",
			"Phase": "Phase 2",
			"Status": "Active, not recruiting",
			"Target": "IL31RA",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000164509",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05214794"],
			"Sponsor": "Maruho Co., Ltd."
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "ABATACEPT",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201823",
			"Type": "Protein",
			"Mechanism of Action": "T-lymphocyte activation antigen CD86 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "CD86",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000114013",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02161406"],
			"Sponsor": "University of Michigan"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "DERSIMELAGON",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4802160",
			"Type": "Small molecule",
			"Mechanism of Action": "Melanocortin receptor 1 agonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "MC1R",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000258839",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04440592"],
			"Sponsor": "Mitsubishi Tanabe Pharma America Inc."
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "POMALIDOMIDE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL43452",
			"Type": "Small molecule",
			"Mechanism of Action": "CRL4(CRBN) E3 ubiquitin ligase inhibitor",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "RBX1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000100387",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01559129"],
			"Sponsor": "Celgene"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "BRENTUXIMAB VEDOTIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1742994",
			"Type": "Antibody drug conjugate",
			"Mechanism of Action": "Tubulin inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TUBB2B",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000137285",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03222492",
				"https://clinicaltrials.gov/study/NCT03198689"
			],
			"Sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "LANIFIBRANOR",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4091374",
			"Type": "Small molecule",
			"Mechanism of Action": "Peroxisome proliferator-activated receptor agonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "PPARD",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000112033",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02503644"],
			"Sponsor": "Inventiva Pharma"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "LANIFIBRANOR",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4091374",
			"Type": "Small molecule",
			"Mechanism of Action": "Peroxisome proliferator-activated receptor agonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "PPARG",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000132170",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02503644"],
			"Sponsor": "Inventiva Pharma"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "ITACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL3622820",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase JAK1 inhibitor",
			"Phase": "Phase 2",
			"Status": "Recruiting",
			"Target": "JAK1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000162434",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04789850"],
			"Sponsor": "Assistance Publique - Hpitaux de Paris"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "TOFACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL221959",
			"Type": "Small molecule",
			"Mechanism of Action": "Janus Kinase (JAK) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "JAK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000096968",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03274076"],
			"Sponsor": "University of Michigan"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "RIOCIGUAT",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2107834",
			"Type": "Small molecule",
			"Mechanism of Action": "Soluble guanylate cyclase positive allosteric modulator",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "GUCY1B1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000061918",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02283762"],
			"Sponsor": "Bayer"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "BERMEKIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2109653",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-1 alpha inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL1A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000115008",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04045743"],
			"Sponsor": "Hellenic Institute for the Study of Sepsis"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "PREDNISOLONE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL131",
			"Type": "Small molecule",
			"Mechanism of Action": "Glucocorticoid receptor agonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "NR3C1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113580",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03708718"],
			"Sponsor": "University of Manchester"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "BRENTUXIMAB VEDOTIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1742994",
			"Type": "Antibody drug conjugate",
			"Mechanism of Action": "Tubulin inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TUBB1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000101162",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03222492",
				"https://clinicaltrials.gov/study/NCT03198689"
			],
			"Sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "ABATACEPT",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201823",
			"Type": "Protein",
			"Mechanism of Action": "T-lymphocyte activation antigen CD80 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "CD80",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000121594",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02161406"],
			"Sponsor": "University of Michigan"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "TACROLIMUS ANHYDROUS",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL269732",
			"Type": "Small molecule",
			"Mechanism of Action": "FK506-binding protein 1A inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "FKBP1A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000088832",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "LANIFIBRANOR",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4091374",
			"Type": "Small molecule",
			"Mechanism of Action": "Peroxisome proliferator-activated receptor agonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "PPARA",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000186951",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02503644"],
			"Sponsor": "Inventiva Pharma"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "QAX-576",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2109465",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-13 inhibitor",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "IL13",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000169194",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00581997"],
			"Sponsor": "Novartis"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "NILOTINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL255863",
			"Type": "Small molecule",
			"Mechanism of Action": "Bcr/Abl fusion protein",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "BCR",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000186716",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01166139"],
			"Sponsor": "Hospital for Special Surgery, New York"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "BRENTUXIMAB VEDOTIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1742994",
			"Type": "Antibody drug conjugate",
			"Mechanism of Action": "Tumor necrosis factor receptor superfamily member 8 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TNFRSF8",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000120949",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03198689",
				"https://clinicaltrials.gov/study/NCT03222492"
			],
			"Sponsor": "Lawson Health Research Institute"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "VILOBELIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2109636",
			"Type": "Antibody",
			"Mechanism of Action": "Complement C5 inhibitor",
			"Phase": "Phase 2",
			"Status": "Active, not recruiting",
			"Target": "C5",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000106804",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04812535"],
			"Sponsor": "InflaRx GmbH"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "GUSELKUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2364648",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-23 inhibitor",
			"Phase": "Phase 2",
			"Status": "Active, not recruiting",
			"Target": "IL23A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000110944",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04683029"],
			"Sponsor": "Janssen Pharmaceutical K.K."
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "TOFACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL221959",
			"Type": "Small molecule",
			"Mechanism of Action": "Janus Kinase (JAK) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "TYK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105397",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03274076"],
			"Sponsor": "University of Michigan"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "MYCOPHENOLIC ACID",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL866",
			"Type": "Small molecule",
			"Mechanism of Action": "Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "IMPDH2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000178035",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "METHOTREXATE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL34259",
			"Type": "Small molecule",
			"Mechanism of Action": "Dihydrofolate reductase inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "DHFR",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000228716",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00241189"],
			"Sponsor": "University of California, Los Angeles"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "THALIDOMIDE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL468",
			"Type": "Small molecule",
			"Mechanism of Action": "CRL4(CRBN) E3 ubiquitin ligase inhibitor",
			"Phase": "Phase 1",
			"Status": "Terminated",
			"Target": "CRBN",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113851",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00418132"],
			"Sponsor": "NYU Langone Health"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "TEPROTUMUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1743079",
			"Type": "Antibody",
			"Mechanism of Action": "Insulin-like growth factor I receptor antagonist",
			"Phase": "Phase 1",
			"Status": "Terminated",
			"Target": "IGF1R",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000140443",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04478994"],
			"Sponsor": "Amgen"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "FRESOLIMUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1743022",
			"Type": "Antibody",
			"Mechanism of Action": "Transforming growth factor beta-1 inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "TGFB1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105329",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01284322"],
			"Sponsor": "Boston University"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "DIVALPROEX SODIUM",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2105613",
			"Type": "Small molecule",
			"Mechanism of Action": "Succinate semialdehyde dehydrogenase inhibitor",
			"Phase": "Phase 1",
			"Status": "Withdrawn",
			"Target": "ALDH5A1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000112294",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02166229"],
			"Sponsor": "Yale University"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "RILONACEPT",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201830",
			"Type": "Protein",
			"Mechanism of Action": "Interleukin-1 beta inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "IL1B",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000125538",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01538719"],
			"Sponsor": "Boston University"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "BRODALUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1742996",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-17 receptor A antagonist",
			"Phase": "Phase 1",
			"Status": "Active, not recruiting",
			"Target": "IL17RA",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000177663",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04368403"],
			"Sponsor": "Kyowa Kirin Co., Ltd."
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "FRESOLIMUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1743022",
			"Type": "Antibody",
			"Mechanism of Action": "Transforming growth factor beta-3 inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "TGFB3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000119699",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01284322"],
			"Sponsor": "Boston University"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "THALIDOMIDE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL468",
			"Type": "Small molecule",
			"Mechanism of Action": "CRL4(CRBN) E3 ubiquitin ligase inhibitor",
			"Phase": "Phase 1",
			"Status": "Terminated",
			"Target": "CUL4A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000139842",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00418132"],
			"Sponsor": "NYU Langone Health"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "VALPROIC ACID",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL109",
			"Type": "Small molecule",
			"Mechanism of Action": "Succinate semialdehyde dehydrogenase inhibitor",
			"Phase": "Phase 1",
			"Status": "Withdrawn",
			"Target": "ALDH5A1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000112294",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02166229"],
			"Sponsor": "Yale University"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "THALIDOMIDE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL468",
			"Type": "Small molecule",
			"Mechanism of Action": "CRL4(CRBN) E3 ubiquitin ligase inhibitor",
			"Phase": "Phase 1",
			"Status": "Terminated",
			"Target": "DDB1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000167986",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00418132"],
			"Sponsor": "NYU Langone Health"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "THALIDOMIDE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL468",
			"Type": "Small molecule",
			"Mechanism of Action": "CRL4(CRBN) E3 ubiquitin ligase inhibitor",
			"Phase": "Phase 1",
			"Status": "Terminated",
			"Target": "RBX1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000100387",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00418132"],
			"Sponsor": "NYU Langone Health"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "MYCOPHENOLIC ACID",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL866",
			"Type": "Small molecule",
			"Mechanism of Action": "Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "IMPDH1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000106348",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00622895"],
			"Sponsor": "Fred Hutchinson Cancer Center"
		},
		{
			"Disease": "diffuse scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000404",
			"Drug": "FRESOLIMUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1743022",
			"Type": "Antibody",
			"Mechanism of Action": "Transforming growth factor beta-2 inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "TGFB2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000092969",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01284322"],
			"Sponsor": "Boston University"
		},
		{
			"Disease": "systemic scleroderma",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_0000717",
			"Drug": "BUSPIRONE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL49",
			"Type": "Small molecule",
			"Mechanism of Action": "Serotonin 1a (5-HT1a) receptor partial agonist",
			"Phase": "Phase 0.5",
			"Status": "Completed",
			"Target": "HTR1A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000178394",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02363478"],
			"Sponsor": "Laik General Hospital, Athens"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "ADALIMUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201580",
			"Type": "Antibody",
			"Mechanism of Action": "TNF-alpha inhibitor",
			"Phase": "Phase 4",
			"Status": "Completed",
			"Target": "TNF",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000232810",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02808975"],
			"Sponsor": "AbbVie"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "ONABOTULINUMTOXINA",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201574",
			"Type": "Unknown",
			"Mechanism of Action": "Synaptosomal-associated protein 25 inhibitor",
			"Phase": "Phase 4",
			"Status": "Not yet recruiting",
			"Target": "SNAP25",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000132639",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT06237465"],
			"Sponsor": "Yale University"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "SPIRONOLACTONE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1393",
			"Type": "Small molecule",
			"Mechanism of Action": "Mineralocorticoid receptor antagonist",
			"Phase": "Phase 4",
			"Status": "Withdrawn",
			"Target": "NR3C2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000151623",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04100083"],
			"Sponsor": "Medical University of South Carolina"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "TRIAMCINOLONE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1451",
			"Type": "Small molecule",
			"Mechanism of Action": "Glucocorticoid receptor agonist",
			"Phase": "Phase 4",
			"Status": "Terminated",
			"Target": "NR3C1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113580",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04582669"],
			"Sponsor": "Montefiore Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFAF2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000164182",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "MT-ND4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000198886",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000189043",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "MT-ND1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000198888",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA5",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000128609",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA10",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000130414",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFS4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000164258",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "UPADACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL3622821",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase JAK2 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "JAK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000096968",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04430855"],
			"Sponsor": "AbbVie"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "MT-ND3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000198840",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFB3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000119013",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFB9",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000147684",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFB2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000090266",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "SPESOLIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297911",
			"Type": "Antibody",
			"Mechanism of Action": "IL36 receptor antagonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL1RAP",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196083",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04762277"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA12",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000184752",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA9",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000139180",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "BIMEKIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297700",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-17F inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "IL17F",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000112116",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT04242446",
				"https://clinicaltrials.gov/study/NCT04242498"
			],
			"Sponsor": "UCB Pharma"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "UPADACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL3622821",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase JAK1 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "JAK1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000162434",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04430855"],
			"Sponsor": "AbbVie"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFAF1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000137806",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFB7",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000099795",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "MT-ND5",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000198786",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFB5",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000136521",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000131495",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFS7",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000115286",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFAF3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000178057",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFS5",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000168653",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000125356",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA4L2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000185633",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFC2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000151366",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "UPADACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL3622821",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase JAK3 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "JAK3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105639",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04430855"],
			"Sponsor": "AbbVie"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFB11",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000147123",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "SECUKINUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1743068",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin 17A inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "IL17A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000112115",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03713619",
				"https://clinicaltrials.gov/study/NCT03713632"
			],
			"Sponsor": "Novartis"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "BIMEKIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297700",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin 17A inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "IL17A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000112115",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT04242498",
				"https://clinicaltrials.gov/study/NCT04242446"
			],
			"Sponsor": "UCB Pharma"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFAB1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000004779",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "SPESOLIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297911",
			"Type": "Antibody",
			"Mechanism of Action": "IL36 receptor antagonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL1RL2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000115598",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04762277"],
			"Sponsor": "Boehringer Ingelheim"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFB4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000065518",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "UPADACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL3622821",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase TYK2 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TYK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105397",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04430855"],
			"Sponsor": "AbbVie"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA6",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000184983",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFC1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000109390",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFV2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000178127",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "MT-ND2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000198763",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFS8",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000110717",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFV1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000167792",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFS1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000023228",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA13",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000186010",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA11",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000174886",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "MT-ND6",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000198695",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFS2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000158864",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "IZOKIBEP",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297686",
			"Type": "Protein",
			"Mechanism of Action": "Interleukin 17A inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL17A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000112115",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05355805"],
			"Sponsor": "ACELYRIN Inc."
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFB8",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000166136",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFB6",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000165264",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "MT-ND4L",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000212907",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFB10",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000140990",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA8",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000119421",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000170906",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFAF4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000123545",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFS3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000213619",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "GPD2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000115159",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFB1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000183648",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFS6",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000145494",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFA7",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000267855",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "METFORMIN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1431",
			"Type": "Small molecule",
			"Mechanism of Action": "Mitochondrial complex I (NADH dehydrogenase) inhibitor",
			"Phase": "Phase 3",
			"Status": "Completed",
			"Target": "NDUFV3",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000160194",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04649502"],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "RUXOLITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1789941",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase JAK2 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "JAK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000096968",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05635838"],
			"Sponsor": "Incyte Corporation"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "RISANKIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL3990029",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-23 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL23A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000110944",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03926169"],
			"Sponsor": "AbbVie"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "ROPSACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4459585",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase TYK2 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TYK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105397",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04092452"],
			"Sponsor": "Pfizer"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "LUTIKIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4594518",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-1 alpha inhibitor",
			"Phase": "Phase 2",
			"Status": "Recruiting",
			"Target": "IL1A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000115008",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05139602"],
			"Sponsor": "AbbVie"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "APREMILAST",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL514800",
			"Type": "Small molecule",
			"Mechanism of Action": "Phosphodiesterase 4 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "PDE4D",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113448",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03049267",
				"https://clinicaltrials.gov/study/NCT02695212"
			],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "DEUCRAVACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4435170",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase TYK2 negative allosteric modulator",
			"Phase": "Phase 2",
			"Status": "Recruiting",
			"Target": "TYK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105397",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05997277"],
			"Sponsor": "Beth Israel Deaconess Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "DROSPIRENONE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1509",
			"Type": "Small molecule",
			"Mechanism of Action": "Mineralocorticoid receptor antagonist",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "NR3C2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000151623",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00722800"],
			"Sponsor": "Massachusetts General Hospital"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "ETANERCEPT",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201572",
			"Type": "Protein",
			"Mechanism of Action": "TNF-alpha inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TNF",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000232810",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT00329823",
				"https://clinicaltrials.gov/study/NCT00107991"
			],
			"Sponsor": "University of Athens"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "ISCALIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4298210",
			"Type": "Antibody",
			"Mechanism of Action": "Tumor necrosis factor receptor superfamily member 5 inhibitor",
			"Phase": "Phase 2",
			"Status": "Recruiting",
			"Target": "CD40",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000101017",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03827798"],
			"Sponsor": "Novartis"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "BREPOCITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297477",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase TYK2 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TYK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105397",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04092452"],
			"Sponsor": "Pfizer"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "M-1095",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4298023",
			"Type": "Unknown",
			"Mechanism of Action": "Interleukin 17A inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL17A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000112115",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05322473"],
			"Sponsor": "MoonLake Immunotherapeutics AG"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "ANIFROLUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2364653",
			"Type": "Antibody",
			"Mechanism of Action": "Interferon-alpha/beta receptor alpha chain antagonist",
			"Phase": "Phase 2",
			"Status": "Not yet recruiting",
			"Target": "IFNAR1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000142166",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT06374212"],
			"Sponsor": "University of North Carolina, Chapel Hill"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "BREPOCITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297477",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase JAK1 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "JAK1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000162434",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04092452"],
			"Sponsor": "Pfizer"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "APREMILAST",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL514800",
			"Type": "Small molecule",
			"Mechanism of Action": "Phosphodiesterase 4 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "PDE4B",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000184588",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT02695212",
				"https://clinicaltrials.gov/study/NCT03049267"
			],
			"Sponsor": "Florida Academic Dermatology Centers"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "AVACOPAN",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL3989871",
			"Type": "Small molecule",
			"Mechanism of Action": "C5a anaphylatoxin chemotactic receptor antagonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "C5AR1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000197405",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03852472"],
			"Sponsor": "ChemoCentryx"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "FOSTAMATINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2103830",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase SYK inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "SYK",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000165025",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05040698"],
			"Sponsor": "Holdsworth House Medical Practice"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "RUXOLITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1789941",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase JAK1 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "JAK1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000162434",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05635838"],
			"Sponsor": "Incyte Corporation"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "MEDI-8968",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2109607",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-1 receptor inhibitor",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "IL1R1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000115594",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01838499"],
			"Sponsor": "AstraZeneca"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "IMSIDOLIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4650441",
			"Type": "Antibody",
			"Mechanism of Action": "IL36 receptor antagonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL1RL2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000115598",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04856930"],
			"Sponsor": "AnaptysBio, Inc."
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "USTEKINUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201835",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-23 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL12B",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000113302",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT01704534"],
			"Sponsor": "University Medical Center Groningen"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "IMSIDOLIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4650441",
			"Type": "Antibody",
			"Mechanism of Action": "IL36 receptor antagonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL1RAP",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196083",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04856930"],
			"Sponsor": "AnaptysBio, Inc."
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "CJM-112",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297926",
			"Type": "Unknown",
			"Mechanism of Action": "Interleukin 17A binding agent",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL17A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000112115",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT02421172"],
			"Sponsor": "Novartis"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "BERMEKIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2109653",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-1 alpha inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL1A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000115008",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT04019041",
				"https://clinicaltrials.gov/study/NCT03512275",
				"https://clinicaltrials.gov/study/NCT02643654"
			],
			"Sponsor": "Janssen Research &amp; Development, LLC"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "APREMILAST",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL514800",
			"Type": "Small molecule",
			"Mechanism of Action": "Phosphodiesterase 4 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "PDE4A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000065989",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03049267",
				"https://clinicaltrials.gov/study/NCT02695212"
			],
			"Sponsor": "Erasmus Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "LUTIKIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4594518",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-1 beta inhibitor",
			"Phase": "Phase 2",
			"Status": "Recruiting",
			"Target": "IL1B",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000125538",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05139602"],
			"Sponsor": "AbbVie"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "ANAKINRA",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201570",
			"Type": "Protein",
			"Mechanism of Action": "Interleukin-1 receptor antagonist",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL1R1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000115594",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT01558375",
				"https://clinicaltrials.gov/study/NCT01516749"
			],
			"Sponsor": "University of Athens"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "ZIMLOVISERTIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4081711",
			"Type": "Small molecule",
			"Mechanism of Action": "Interleukin-1 receptor-associated kinase 4 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IRAK4",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000198001",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT04092452"],
			"Sponsor": "Pfizer"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "CRAVACITINIB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4596392",
			"Type": "Small molecule",
			"Mechanism of Action": "Tyrosine-protein kinase TYK2 inhibitor",
			"Phase": "Phase 2",
			"Status": "Recruiting",
			"Target": "TYK2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105397",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05997277"],
			"Sponsor": "Beth Israel Deaconess Medical Center"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "APREMILAST",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL514800",
			"Type": "Small molecule",
			"Mechanism of Action": "Phosphodiesterase 4 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "PDE4C",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000105650",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT02695212",
				"https://clinicaltrials.gov/study/NCT03049267"
			],
			"Sponsor": "Florida Academic Dermatology Centers"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "GUSELKUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2364648",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-23 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL23A",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000110944",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT04061395",
				"https://clinicaltrials.gov/study/NCT03628924"
			],
			"Sponsor": "University Medical Center Groningen"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "DROSPIRENONE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1509",
			"Type": "Small molecule",
			"Mechanism of Action": "Progesterone receptor agonist",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "PGR",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000082175",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00722800"],
			"Sponsor": "Massachusetts General Hospital"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "IANALUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4594357",
			"Type": "Antibody",
			"Mechanism of Action": "Tumor necrosis factor receptor superfamily member 13C binding agent",
			"Phase": "Phase 2",
			"Status": "Recruiting",
			"Target": "TNFRSF13C",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000159958",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03827798"],
			"Sponsor": "Novartis"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "M-1095",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL4298023",
			"Type": "Unknown",
			"Mechanism of Action": "Interleukin-17F inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "IL17F",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000112116",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT05322473"],
			"Sponsor": "MoonLake Immunotherapeutics AG"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "ETHINYL ESTRADIOL",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL691",
			"Type": "Small molecule",
			"Mechanism of Action": "Estrogen receptor alpha agonist",
			"Phase": "Phase 2",
			"Status": "Terminated",
			"Target": "ESR1",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000091831",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00722800"],
			"Sponsor": "Massachusetts General Hospital"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "BRODALUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1742996",
			"Type": "Antibody",
			"Mechanism of Action": "Interleukin-17 receptor A antagonist",
			"Phase": "Phase 0.5",
			"Status": "Completed",
			"Target": "IL17RA",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000177663",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT04979520",
				"https://clinicaltrials.gov/study/NCT03960268"
			],
			"Sponsor": "Rockefeller University"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "INFLIXIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201581",
			"Type": "Antibody",
			"Mechanism of Action": "TNF-alpha inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "TNF",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000232810",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00795574"],
			"Sponsor": "Florida Academic Dermatology Centers"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "VILOBELIMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2109636",
			"Type": "Antibody",
			"Mechanism of Action": "Complement C5 inhibitor",
			"Phase": "Phase 2",
			"Status": "Completed",
			"Target": "C5",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000106804",
			"Source URLs": [
				"https://clinicaltrials.gov/study/NCT03487276",
				"https://clinicaltrials.gov/study/NCT03001622"
			],
			"Sponsor": "InflaRx GmbH"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "EFALIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201575",
			"Type": "Antibody",
			"Mechanism of Action": "Integrin alpha-L/beta-2 (LFA-1) inhibitor",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "ITGAL",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000005844",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT00134134"],
			"Sponsor": "NYU Langone Health"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "HYDROXYCHLOROQUINE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1535",
			"Type": "Small molecule",
			"Mechanism of Action": "Toll-like receptor 7 antagonist",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "TLR7",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000196664",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03275870"],
			"Sponsor": "University of Pittsburgh"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "SIPLIZUMAB",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL2108742",
			"Type": "Antibody",
			"Mechanism of Action": "T-cell surface antigen CD2 inhibitor",
			"Phase": "Phase 1",
			"Status": "Not yet recruiting",
			"Target": "CD2",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000116824",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT06326476"],
			"Sponsor": "University of Alabama at Birmingham"
		},
		{
			"Disease": "hidradenitis suppurativa",
			"Disease URL": "https://platform.opentargets.org/disease/EFO_1000710",
			"Drug": "HYDROXYCHLOROQUINE",
			"Drug URL": "https://platform.opentargets.org/drug/CHEMBL1535",
			"Type": "Small molecule",
			"Mechanism of Action": "Toll-like receptor 9 antagonist",
			"Phase": "Phase 1",
			"Status": "Completed",
			"Target": "TLR9",
			"Target URL": "https://platform.opentargets.org/target/ENSG00000239732",
			"Source URLs": ["https://clinicaltrials.gov/study/NCT03275870"],
			"Sponsor": "University of Pittsburgh"
		}
	]
}
